Tumor antigen BFA5 for prevention and / or treatment of cancer
The present invention relates to a nucleic acid encoding a polypeptide and the use of the nucleic acid or polypeptide in preventing and/or treating cancer. In particular, the invention relates to improved vectors for the insertion and expression of foreign genes encoding tumor antigens for use in immunotherapeutic treatment of cancer.
1 . An expression vector comprising the nucleic acid sequence as illustrated in SEQ ID NO.: 5 or FIG. 4 ; a nucleic acid sequence encoding the amino acid sequence illustrated in SEQ ID NO.: 6 or FIG. 5 ; or a fragment thereof.
2 . The expression vector of claim 1 wherein the vector is a plasmid or a viral vector.
3 . The expression vector of claim 2 wherein the viral vector is selected from the group consisting of poxvirus, adenovirus, retrovirus, herpesvirus, and adeno-associated virus.
4 . The expression vector of claim 3 wherein the viral vector is a poxvirus selected from the group consisting of vaccinia, NYVAC, avipox, canarypox, ALVAC, ALVAC(2), fowlpox, and TROVAC.
5 . The expression vector of claim 4 wherein the viral vector is a poxvirus selected from the group consisting of NYVAC, ALVAC, and ALVAC(2).
6 . The expression vector of claim 1 further comprising at least one additional tumor-associated antigen.
7 . The expression vector of claim 6 wherein the vector is a plasmid or a viral vector.
8 . The expression vector of claim 7 wherein the viral vector is selected from the group consisting of poxvirus, adenovirus, retrovirus, herpesvirus, and adeno-associated virus.
9 . The expression vector of claim 8 wherein the viral vector is a poxvirus selected from the group consisting of vaccinia, NYVAC, avipox, canarypox, ALVAC, ALVAC(2), fowlpox, and TROVAC.
10 . The expression vector of claim 9 wherein the viral vector is a poxvirus selected from the group consisting of NYVAC, ALVAC, and ALVAC(2).
11 . The expression vector of claim 1 further comprising at least one nucleic sequence encoding an angiogenesis-associated antigen.
12 . The expression vector of claim 1 wherein the vector is a plasmid or a viral vector.
13 . The expression vector of claim 12 wherein the viral vector is selected from the group consisting of poxvirus, adenovirus, retrovirus, herpesvirus, and adeno-associated virus.
14 . The expression vector of claim 13 wherein the viral vector is a poxvirus selected from the group consisting of vaccinia, NYVAC, avipox, canarypox, ALVAC, ALVAC(2), fowlpox, and TROVAC.
15 . The expression vector of claim 14 wherein the viral vector is a poxvirus selected from the group consisting of NYVAC, ALVAC, and ALVAC(2).
16 . The expression vector of claim 6 further comprising at least one nucleic sequence encoding an angiogenesis-associated antigen.
17 . The expression vector of claim 16 wherein the vector is a plasmid or a viral vector.
18 . The expression vector of claim 17 wherein the viral vector is selected from the group consisting of poxvirus, adenovirus, retrovirus, herpesvirus, and adeno-associated virus.
19 . The expression vector of claim 17 wherein the viral vector is a poxvirus selected from the group consisting of vaccinia, NYVAC, avipox, canarypox, ALVAC, ALVAC(2), fowlpox, and TROVAC.
20 . The expression vector of claim 18 wherein the viral vector is a poxvirus selected from the group consisting of NYVAC, ALVAC, and ALVAC(2).
21 . An expression vector selected from the group consisting of an expression vector of claim 1 , an expression vector of claim 6 , an expression vector of claim 11 , and an expression vector of claim 16; further comprising a nucleic acid sequence encoding a co-stimulatory molecule.
22 . The expression vector of claim 22 wherein the vector is a plasmid or a viral vector.
23 . The expression vector of claim 23 wherein the viral vector is selected from the group consisting of poxvirus, adenovirus, retrovirus, herpesvirus, and adeno-associated virus.
24 . The expression vector of claim 24 wherein the viral vector is a poxvirus selected from the group consisting of vaccinia, NYVAC, avipox, canarypox, ALVAC, ALVAC(2), fowlpox, and TROVAC.
25 . The expression vector of claim 18 wherein the viral vector is a poxvirus selected from the group consisting of NYVAC, ALVAC, and ALVAC(2).
26 . A composition comprising an expression vector in a pharmaceutically acceptable carrier, said vector comprising the nucleic acid sequence shown in SEQ ID NO.:5 or FIG. 4 ; a nucleic acid sequence encoding the amino acid sequence illustrated in SEQ ID NO.: 6 or FIG. 5 ; or a fragment thereof.
27 . The composition of claim 26 wherein the vector is a plasmid or a viral vector.
28 . The composition of claim 27 wherein the viral vector is selected from the group consisting of poxvirus, adenovirus, retrovirus, herpesvirus, and adeno-associated virus.
29 . The composition of claim 28 wherein the viral vector is a poxvirus selected from the group consisting of vaccinia, NYVAC, avipox, canarypox, ALVAC, ALVAC(2), fowlpox, and TROVAC.
30 . The composition of claim 29 wherein the viral vector is a poxvirus selected from the group consisting of NYVAC, ALVAC, and ALVAC(2).
31 . A method for preventing or treating cancer comprising administering to a host an expression vector comprising the nucleic acid sequence illustrated in SEQ ID NO.: 5 or FIG. 4 ; a nucleic acid encoding the amino acid sequence illustrated in SEQ ID NO.: 6 or FIG. 5 ; or a fragment thereof.
32 . The method of claim 31 wherein the vector is a plasmid or a viral vector.
33 . The method of claim 32 wherein the viral vector is selected from the group consisting of poxvirus, adenovirus, retrovirus, herpesvirus, and adeno-associated virus.
34 . The method of claim 33 wherein the viral vector is a poxvirus selected from the group consisting of vaccinia, NYVAC, avipox, canarypox, ALVAC, ALVAC(2), fowlpox, and TROVAC.
35 . The method of claim 34 wherein the viral vector is a poxvirus selected from the group consisting of NYVAC, ALVAC, and ALVAC(2).
36 . An isolated peptide derived from BFA5 as shown in Table X or XI.
37 . A method for immunizing a host against the tumor antigen BFA5 comprising administering to the patient a peptide shown in Table X or XI, either alone or in combination with another agent, where the individual components of the combination are administered simultaneously or separately from one another.
38 . An isolated peptide derived from BFA5 as shown in Table X or XI.
39 . A method for immunizing a host against the tumor antigen BFA5 comprising administering to the patient a peptide shown in Table X or XI, either alone or in combination with another agent, where the individual components of the combination are administered simultaneously or separately from one another.
40 . The expression vector of claim 6 wherein the additional tumor-associated antigen is encoded by a nucleic acid sequence selected from the group consisting of SEQ ID NO.: 1; SEQ ID NO.: 3; the nucleic acid sequence shown in FIG. 1 ; the nucleic sequence illustrated in FIG. 3A ; a nucleic acid sequence encoding the amino acid sequence of SEQ ID NO.: 2; a nucleic acid sequence encoding the amino acid sequence of SEQ ID NO.: 4; the nucleic acid sequence encoding the amino acid sequence illustrated in FIG. 2 ; a nucleic acid sequence encoding the amino acid sequence illustrated in FIG. 3B ; a nucleic acid hybridizable under stringent conditions to any of the foregoing sequences; a fragment of any of the foregoing nucleic acid sequences; and, a derivative of any of the foregoing nucleic acid sequences.
41 . The expression vector of claim 40 wherein the viral vector is selected from the group consisting of poxvirus, adenovirus, retrovirus, herpesvirus, and adeno-associated virus.
42 . The expression vector of claim 41 wherein the viral vector is a poxvirus selected from the group consisting of vaccinia, NYVAC, avipox, canarypox, ALVAC, ALVAC(2), fowlpox, and TROVAC.
43 . The expression vector of claim 42 wherein the viral vector is a poxvirus selected from the group consisting of NYVAC, ALVAC, and ALVAC(2).
44 . An expression vector selected from the group consisting of an expression vector of claim 40 , an expression vector of claim 41 , an expression vector of claim 42 , and an expression vector of claim 42; further comprising a nucleic acid sequence encoding a co-stimulatory molecule.
45 . An expression vector of claim 44 or claim 21 wherein the co-stimulatory molecule is human B7.1 or a derivative thereof.
46 . A composition comprising an expression vector of claim 40 in a pharmaceutically acceptable carrier.
47 . A composition comprising an expression vector of claim 41 in a pharmaceutically acceptable carrier.
48 . A composition comprising an expression vector of claim 42 in a pharmaceutically acceptable carrier.
49 . A composition comprising an expression vector of claim 43 in a pharmaceutically acceptable carrier.
50 . A composition comprising an expression vector of claim 44 in a pharmaceutically acceptable carrier.
51 . A composition comprising an expression vector of claim 45 in a pharmaceutically acceptable carrier.
52 . A method for preventing or treating cancer comprising administering to a host a composition of claim 46 .
53 . A method for preventing or treating cancer comprising administering to a host a composition of claim 47 .
54 . A method for preventing or treating cancer comprising administering to a host a composition of claim 48 .
55 . A method for preventing or treating cancer comprising administering to a host a composition of claim 49 .
56 . A method for preventing or treating cancer comprising administering to a host a composition of claim 50 .
57 . A method for preventing or treating cancer comprising administering to a host a composition of claim 51 .
58 . An isolated DNA molecule comprising the nucleic acid of SEQ ID NO.:5 and at least one of the nucleic acid sequences of SEQ ID NO.: 3 or SEQ ID NO.: 5.
59 . An expression vector comprising the isolated DNA molecule of claim 58 .
60 . An isolated DNA molecule comprising a nucleic acid encoding the amino acid sequence of SEQ ID NO. 6 and at least one of the amino acid sequences of SEQ ID NO.: 2 or SEQ ID NO.: 4.
61 . An expression vector comprising the isolated DNA molecule of claim 60 .
62 . An isolated DNA molecule comprising the nucleic acid of SEQ ID NO.:5 and at least one of the nucleic acid sequences of SEQ ID NO.: 3 or SEQ ID NO.: 5; a nucleic acid hybridizable under stringent conditions to the nucleic acid sequences of SEQ ID NO.: 3 or SEQ ID NO.: 5; a fragment of the nucleic acid sequences of SEQ ID NO.: 3 or SEQ ID NO.: 5; and, a derivative of any of the nucleic acid sequences of SEQ ID NO.: 3 or SEQ ID NO.: 5.
63 . An antibody having the ability to bind the amino acid sequence of SEQ ID NO.: 6 or a fragment the amino acid sequence of SEQ ID NO.: 6.